Head-to-head comparison of two human papillomavirus vaccines for efficacy against cervical intraepithelial neoplasia grade 3 and adenocarcinoma in situ—population-based follow-up of two cluster-randomized trials
Frontiers in Cellular and Infection Microbiology · 2024
DOI: 10.3389/fcimb.2024.1437704 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2024. Verfasst von Matti Lehtinen und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of CLINTEC, Karolinska Institute, Stockholm, Sweden. Hauptthemen laut MEDLINE: Uterine Cervical Dysplasia, Papillomavirus Vaccines, Papillomavirus Infections, Uterine Cervical Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
We report head-to-head comparison of the bivalent and quadrivalent HPV vaccine efficacies against immediate precursors of cervical cancer from 15 years’ country-wide cancer registry follow-up of phase III trial cohorts and an age-aligned cohort of unvaccinated women.
Methods
These individually and/or clusterrandomized cohorts of HPV6/11/16/18- and HPV16/18-vaccinated and unvaccinated women were enrolled, respectively, in 2002, 2004, and 2003/2005. The trial cohorts comprised initially 16- to 17-year-old HPV6/11/16/18-vaccinated FUTURE II (NCT00092534) participants (866) and HPV16/18-vaccinated PATRICIA (NCT00122681) and 012 trial (NCT00169494) participants (2,465), and 16,526 initially 16- to 19-year-old unvaccinated controls. After active 4-year clinical follow-up, passive, country-wide Finnish Cancer Registry (FCR) follow-up for cervical intraepithelial neoplasia grade 3 (CIN3) and adenocarcinoma in situ (AIS) was based on consented use of unique personal identifiers and started 6 months after the end of the FUTURE II and PATRICIA trials in 2007 and 2009, and ended at the end of 2019. The follow-up with altogether 229,020 follow-up years was age-aligned to ensure that similarly aged cohorts were passively followed up for 15 years post=vaccination for the intention-to-treat analyses of vaccine efficacy.
Results
Overall, we identified 5 and 16 CIN3 (no AIS) cases in the HPV6/11/16/18 and HPV16/18 cohorts, respectively, during the FCR-based follow-up. In the unvaccinated cohort, we identified 281 CIN3 cases, 20 AIS cases, and 13 cases with invasive cervical cancer. Vaccine efficacies against CIN3+ were 68.4% and 64.5% for the quadrivalent and the bivalent vaccines, respectively, with overlapping confidence intervals.
Discussion
Long-term follow-up of randomized, initially adolescent HPV-vaccinated and unvaccinated cohorts shows, in this head-to-head setting, that the bivalent and quadrivalent HPV vaccines are equally effective against immediate precursors of cervical cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of CLINTEC, Karolinska Institute, Stockholm, Sweden.
- Faculty of Medicine, Tampere University, Tampere, Finland.
- Institute for Epidemiological Cancer Research, Finnish Cancer Registry, Helsinki, Finland.
- Youth Clinic, VL-Medi, Helsinki, Finland.
- Department of Obstetrics and Gynecology, University of Helsinki, Helsinki, Finland.
- Department of Obstetrics and Gynecology, University of East-Finland, Kuopio, Finland.
Zitieren
APA
Lehtinen, M., Gray, P., Luostarinen, T., Eriksson, T., Apter, D., Bly, A., Harjula, K., Heikkilä, K., Hokkanen, M., Kuortti, M., Nieminen, P., Nummela, M., Paavonen, J., Palmroth, J., Petäjä, T., Pimenoff, V. N., Pukkala, E., & Dillner, J. (2024). Head-to-head comparison of two human papillomavirus vaccines for efficacy against cervical intraepithelial neoplasia grade 3 and adenocarcinoma in situ—population-based follow-up of two cluster-randomized trials. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2024.1437704
Vancouver
Lehtinen M, Gray P, Luostarinen T, Eriksson T, Apter D, Bly A, et al. Head-to-head comparison of two human papillomavirus vaccines for efficacy against cervical intraepithelial neoplasia grade 3 and adenocarcinoma in situ—population-based follow-up of two cluster-randomized trials. Frontiers in Cellular and Infection Microbiology. 2024. doi:10.3389/fcimb.2024.1437704
BibTeX
@article{Lehtinen2024,
author = {Lehtinen, Matti and Gray, Penelope and Luostarinen, Tapio and Eriksson, Tiina and Apter, Dan and Bly, Anne and Harjula, Katja and Heikkilä, Kaisa and Hokkanen, Mari and Kuortti, Marjo and Nieminen, Pekka and Nummela, Mervi and Paavonen, Jorma and Palmroth, Johanna and Petäjä, Tiina and Pimenoff, Ville N and Pukkala, Eero and Dillner, Joakim},
title = {Head-to-head comparison of two human papillomavirus vaccines for efficacy against cervical intraepithelial neoplasia grade 3 and adenocarcinoma in situ—population-based follow-up of two cluster-randomized trials},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2024},
doi = {10.3389/fcimb.2024.1437704}
}
EUVIMED